Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride

Fuji Yokoi, Gerhard Gründer, Kathleen Biziere, Massoud Stephane, Ahmet S. Dogan, Robert F. Dannals, Hayden Ravert, Ajit Suri, Steven Bramer, Dean F. Wong

Research output: Contribution to journalArticle

255 Scopus citations


Aripiprazole (OPC 14597) is an antipsychotic drug that has high affinity for dopamine D2 and D3 receptors and the dopamine autoreceptor. It is being developed for treatment of patients with schizophrenia. The purpose of this study was to determine whether a dose response following graduated doses of aripiprazole could be quantified and correlated with its occupancy of the D2 and D3 dopamine receptors in the brain of living humans. Dopamine D2 and D3 receptor occupancy in fifteen normal male human brains was measured using positron emission tomography (PET) with [11C]raclopride. PET studies were performed before and after two weeks of administration of aripiprazole. The dopamine D2 receptor occupancy was quantified with two kinetic modeling methods without using a blood input function. Administration of aripiprazole for 14 days resulted in a dose-dependent receptor occupancy between 40 - 95% after the administration of 0.5mg, 1 mg, 2 mg, 10 mg, and 30 mg per day. These results suggest that an adequate occupancy can be obtained, and this may be useful to predict an appropriate therapeutic dose for an individual patient. Interestingly, even at striatal D2 receptor occupancy values above 90%, which occurred with the higher doses, extrapyramidal side effects (EPS) were not observed. This underlines aripiprazole's unique mechanism of action as a partial dopamine receptor agonist, which might become a novel principle in the treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)248-259
Number of pages12
Issue number2
Publication statusPublished - 2002
Externally publishedYes



  • [C]raclopride
  • Aripiprazole
  • D dopamine receptor
  • Dopamine agonist
  • Positron Emission Tomography (PET)
  • Receptor occupancy
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this